Biosergen's CEO Peder M. Andersen comments:

"I am very pleased that we have been able to attract an international capacity like Tine Kold Olesen as our new Chief Operating Officer. Tine is a hands-on drug developer who is able to focus on the details while still keeping the overall objectives and long term strategies in sight. This is exactly what we need at this stage of our development and I wish her a warm welcome."

About Tine Kold Olesen

Tine Kold Olesen started her career in the clinical research field in international pharmaceutical companies Novo Nordisk, Glaxo-Welcome and Orion Pharma. From 2001 to 2020 she held positions of ever increasing responsibility in Ferring Pharmaceuticals, ending with her appointment to Senior Director, Global Project and Portfolio Management in Ferring Inc., USA where she managed Ferring's entire Oncology/Urology portfolio in the United States.

Tine Kold Olesen completed her MSc at the Copenhagen Faculty of Pharmacy in 1992. In 2012 she obtained an Executive MBA from Imperial College, London. Recently, she completed her PhD at the faculty of Medicine and Health Sciences from the University of Gent, Belgium. She will join Biosergen on October 1, 2021.

For further information about Biosergen, please contact:

CEO Peder M. Andersen MD

Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

ABOUT BIOSERGEN

Biosergen is a No-Research-Development-Only biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States and expects to file the NDA by the end of 2025.